Data / Form D filings / TriSalus Life Sciences, Inc.
TriSalus Life Sciences, Inc.: Form D filings
TriSalus Life Sciences, Inc., a biotechnology company in Westminster, CO, filed 3 Form D notices with the SEC between 2023 and 2025. The latest, on May 8, 2025, reports $22 million sold of a $22 million offering to 24 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 6272 WEST 91ST AVENUE, Westminster, CO, 80031
- Phone
- (415) 336-8917
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2020
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1826667
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| May 8, 2025 | New notice | $22,000,000 | $22,000,000 | 24 | May 2, 2025 | sec.gov | |
| Dec 30, 2024 | New notice | $999,984 | $999,984 | 6 | Dec 17, 2024 | sec.gov | |
| Jun 22, 2023 | New notice | $50,000,000 | $17,855,020 | $32,144,980 | 17 | Jun 7, 2023 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Mats J. Wahlstrom | Director | |
| Jennifer J. Stevens | Executive Officer | |
| David J. Matlin | Director | |
| Jodi J. Devlin | Executive Officer | |
| Arjun F. Desai | Director | |
| Sean Murphy | Director | |
| Richard J. Marshak | Executive Officer | |
| Gary F. Gordon | Director | |
| James Young | Executive Officer | |
| Mary Szela | Executive Officer, Director | |
| Andrew F. von Eschenbach | Director | |
| Kerry F. Hicks | Director | |
| Brian F. Cox | Executive Officer | |
| William F. Valle | Director |
Other biotechnology companies in Colorado that filed recently
- GelSana Therapeutics, Inc. $4.4 million · Oct 8, 2026
- Renovare Therapeutics, Inc. $100,000 · Oct 2, 2026
- EnteroTrack, LLC $2 million · Sep 25, 2026
- Shiverbright Technologies, Inc. $200,000 · Aug 7, 2026
Every Form D from the week of May 5, 2025 · All recent filings in Colorado · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what TriSalus Life Sciences, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.